Biotechnology Law Report

Papers
(The median citation count of Biotechnology Law Report is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
To What Extent Does Mayo v. Prometheus Allow for the Patenting of Diagnostic Methods?26
Patents Cannot Be Blamed for Inequitable Access to COVID-19 Vaccines4
The Localization of Drug Patent Linkage System in China: Where Should It Go?3
Trade Secret Protection on a Publicly Sold, Patented Spinal Implant Device: Life Spine, Inc. v. Aegis Spine, Inc.3
CareDx, Inc. v. Natera, Inc. United States Court of Appeals of the Federal Circuit, 2022 40 F.4th 13713
Legal Governance of Human Gene Editing Technology: From Single Governance to Multiple Governance2
Selected Developments in Biotechnology Law and the Biotechnology Industry2
Selected Developments in Biotechnology Law and the Biotechnology Industry2
Is Cross-Border Transfer of Human Genetic Data an Impossible Mission?2
Selected Developments in Biotechnology Law and the Biotechnology Industry2
Amgen v. Sanofi: The Supreme Court Takes up the Enablement Requirement in the Context of Therapeutic Monoclonal Antibodies2
Nippon Shinyaku Co. v. Sarepta Therapeutics, Inc.2
ModernaTx, Inc. v. Arbutus Biopharma Corp.1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Research on the Latest Progress of “Mechanism for Early Resolution of Patent Disputes” for Biological Products in China1
Moo-re Gene-edited Animals Get Regulatory Clearance: U.S. FDA Approves Genetically Engineered Cattle for Human Consumption1
Recent Developments in FDA Regulatory Exclusivities1
Observation on China's Performance in the Global Supply Chain of COVID-19 Medicine1
Hologic, Inc. v. Minerva Surgical, Inc.1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Tris Pharma, Inc. v. Actavis Lab'ys FL, Inc.1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Federal Circuit Reiterates That Drug Safety and Efficacy Are Issues for the FDA, Not the Patent Laws1
Pac. Biosciences of California, Inc. v. Pers. Genomics Taiwan, Inc1
Univ. of Massachusetts v. L'Oreal S.A.1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Astellas Pharma, Inc. v. Sandoz Inc. USA, Inc.1
Agilent Techs., Inc. v. Synthego Corp.1
In re Entresto1
Regents of the Univ. of California v. Broad Inst., Inc.1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Mylan Pharms. Inc. v. Merck Sharp & Dohme Corp. United States Court of Appeals of the Federal Circuit, 2022 50 F.4th 1471
Sanho Corp. v. Kaijet Tech. Int’l Ltd., Inc1
Biotechnology and Intellectual Property Law: Theoretical and Practical Reflections on Albanian National Law and Jurisprudence in Comparison with EU Acquis and ECJ Case Law1
ChromaDex, Inc. v. Elysium Health, Inc. United States Court of Appeals of the Federal Circuit, 2023 59 F.4th 12801
The Redemption of Drug Patent Linkage System: The Dilemma and Improvement in the Qualification System of Market Exclusivity Period for China’s First Generic Drug1
Allgenesis Biotherapeutics Inc. v. Cloudbreak Therapeutics, LLC1
Landscape of Genome Editing Technology Patents in the European Patent Office with a Focus on CRISPR-Related Opposition Proceedings1
ImmunoGen, Inc. v. Stewart1
Generic Drugs and Innovative Drug Incentives: Early Dispute Resolution Mechanism in China1
A 12th Year 101 Update—Diagnostic and DNA Claims Are Patent Eligible, but Pre-Mayo Patents May Continue to Fall1
Eye Therapies, LLC v. Slayback Pharma, LLC1
Incyte Corp. v. Sun Pharm. Indus., Ltd.1
United Therapeutics Corp. v. Liquidia Techs., Inc.1
Dilemma and Solution of Intellectual Property Protection of Biological Genetic Resources1
China's Challenges in Implementing Compulsory Drug Patent Licenses and its Response in the Context of COVID-191
A Review of Patent Regimes on Health Biotechnology Innovation in India1
Galderma Lab’ys, L.P. v. Lupin Inc0
Patentability Analysis of “Intelligent” Disease Diagnosis Methods in China in the Era of Smart Health Care0
Regulation of Biomedical Research: Global and Indian Perspective0
Unproven Stem Cell Industry in the U.S.: Regulatory Challenges and Enforcement Issues0
Wuhan Healthgen Biotechnology Corp. v. Int’l Trade Comm’n0
Cytiva BioProcess R&D AB v. JSR Corp.0
H. Lundbeck A/S v. Lupin Ltd.0
Univ. of S. Fla. Bd. of Trustees v. United States0
Navigating Procedural Challenges in Biotechnological Patenting: A Path Forward for India’s Innovation Landscape0
Univ. of S. Fla. Bd. of Trustees v. United States and the Federal Government’s Nonexclusive License under the Bayh-Dole Act0
Amgen Inc. v. Sandoz Inc. United States Court of Appeals of the Federal Circuit, 2023 No. 2022-1147, 2023 WL 29941660
A Recitation of “Clinically Proven Effective” Fails to “Breathe Patentability” Into Method-of-Treatment Claims0
Recent Developments in the Listing of Patents in FDA's Orange Book0
Jazz Pharms., Inc. v. Avadel CNS Pharms., LLC United States Court of Appeals of the Federal Circuit, 2023 No. 2023-1186, 2023 WL 21986400
Salix Pharms., Ltd. v. Norwich Pharms. Inc.0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Sanofi-Aventis Deutschland GmbH v. Mylan Pharms. Inc.0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Legal Perspective of Genetically Modified Crops and Drowsy Stance of International Actors0
UCB, Inc. v. Actavis Lab'ys UT, Inc.0
The Legal Protection of Gene Private Rights0
A Pharmaceutical Formulation as a Claim Term Cannot “Target” a Plasma Concentration-Time Profile Under 35 U.S.C. § 112: A Lesson from Horizon Pharma, Inc. v. Dr. Reddy's Laboratories Inc.0
Navigating Pharmaceutical Patent Term Extension System in China0
Novartis Pharms. Corp. v. Accord Healthcare, Inc.0
Rosalind Franklin Society Proudly Announces the 2022 Award Recipient for Biotechnology Law Report0
Navigating Cross-Border Challenges In Biobanking: Analysing Eu Legislation, ECJ Case Law, and the Role of Private International Law0
GlaxoSmithKline II and Other Recent Developments in Induced and Contributory Patent Infringement0
Shockwave Med., Inc. v. Cardiovascular Sys., Inc0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
SawStop Holding LLC v. Vidal United States Court of Appeals of the Federal Circuit, 2022 48 F.4th 13550
Rosalind Franklin Society Proudly Announces the 2023 Award Recipient for Biotechnology Law Report0
Janssen Pharms., Inc. v. Teva Pharms. USA, Inc0
A Feasible Pathway for Open Access to Human Embryonic Stem Cell Patents—With China's Open License for Patent as the Entry Point0
The Legislative Paradigm of China's Biosafety Law and Its Positive Significance for the SARS-CoV-2 Prevention and Control0
Innovate, Evaluate, Legislate: U.S. Senators Forge a Path to Assess Artificial Intelligence’s Biosecurity Quandary0
Regeneron Pharms., Inc. v. Mylan Pharms. Inc.0
Restem, LLC v. Jadi Cell, LLC0
Observation on the R&D Effectiveness and Application of China's Novel Coronavirus Vaccine0
Arbutus Biopharma Corp. v. ModernaTX, Inc. United States Court of Appeals of the Federal Circuit, 2023 65 F.4th 6560
Edwards Lifesciences Corp. v. Meril Life Scis. Pvt. Ltd0
In re Entresto and the Standard of Review for Compliance with the Written Description Requirement0
Gilead Scis., Inc. v. United States0
How a Treatment Claim Without Reciting Safety and Efficacy Requirements May Survive the Disclosure Requirement Challenge: United Therapeutics Corp. v. Liquidia Technologies, Inc0
Allergan USA, Inc. v. MSN Lab’ys Priv. Ltd0
Teva Branded Pharmaceutical Products R&D, Inc. v. Amneal Pharmaceuticals of New York, LLC0
Patent Portfolio Landscape in China’s Orange Book : Size Achievements and Persistent Quality Gaps Between Domestic Firms and Multinational Corporations0
The U.S. Patent and Trademark Office Proposes New Rules Targeting Continuation Practice and Terminal Disclaimers0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
In re Xencor, Inc.0
A Look at the Current Status of the CRISPR Patent Interferences Involving Broad Institute, University of California and University of Vienna, ToolGen, and Sigma-Aldrich0
Correction to: AI (Re)Defining Pharmaceutical Exclusivities, by Jonathan Kimball and Srividhya Ragavan, Biotechnol Law Rep 2022;41(1):23–29; doi: 10.1089/blr.2021.29257.sr0
Regeneron Pharms., Inc. v. Mylan Pharms. Inc.0
The Drawing-Up of Laws on Research Involving Human Embryos in Australia: Lack of an Islamic Voice0
In re Couvaras0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Natera, Inc. v. NeoGenomics Lab’ys, Inc0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Should the Federal Circuit Lower the Threshold for Article III Standing to Appeal Adverse Decisions in AIA Trial Proceedings?0
The Evolving Grace Period for U.S. Patent Applicants0
The Fate of FTC v. Actavis, Inc. in the Biosimilar Context—Does and Should the FTC v. Actavis Decision Apply to Reverse Patent Settlements Between Brand Drug and Biosimilar Manufacturers0
The Broad Institute Scores Another Victory in Its Battle with the University of California over the Patenting of CRIPSR0
Regulation of Clinical Trials and Pandemic Research: Upholding Ethical Standards During a COVID-19 Crisis0
Ethical Boundary of the Development of Human Gene Editing Technology0
Oligonucleotide Therapeutics Patenting: Strategies for Success0
Glob. Health Sols. LLC v. Selner0
ModernaTx, Inc. v. Arbutus Biopharma Corp.0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Bayer Pharma Aktiengesellschaft v. Mylan Pharms. Inc0
Novartis Pharms. Corp. v. Accord Healthcare, Inc.0
In re Xencor and the Use of Jepson and Means-Plus-Function Claiming in the Context of Antibody Inventions0
Regulatory Landscape for Generic Drugs in India: Assessing Quality, Safety, and Efficacy Standards0
Gilead Prevails Over the United States Government in Litigation Alleging Patent Infringement (by Gilead) and Breach of Contract (by the United States)0
Pfizer Inc. v. Sanofi Pasteur Inc0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Research on Intellectual Property Right Protection of Genetic Resources in China Under Benefit-Sharing0
Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc.0
Medytox, Inc. v. Galderma S.A.0
The U.S. Patent and Trademark Office’s Response to Recent Developments in Artificial Intelligence0
Genentech, Inc. v. Sandoz, Inc.0
Jazz Pharms., Inc. v. Avadel CNS Pharms., LLC0
Pleading Use of Trade Secrets Concerning a Biological Product by Showing Product-Related Similarities: Allergan, Inc. v. Revance Therapeutics, Inc.0
Minerva Surgical, Inc. v. Hologic, Inc. United States Court of Appeals of the Federal Circuit, 2023 59 F.4th 13710
Actelion Pharms. LTD v. Mylan Pharms. Inc.0
How Science, Technology, and Society Influence Patent Policies: The Choice and Direction of Gene Patent Pathways from the View of Technoscience0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
China Releases Document on Ethics Review of Life Sciences: Comments and Compliance Guidelines0
Teva v. Amneal: The Federal Circuit Weighs in on the Listing of Patents Relating to Drug-Device Combinations in the Orange Book0
Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part I0
AI (Re)Defining Pharmaceutical Exclusivities0
Incyte Corp. v. Sun Pharm. Indus., Ltd.0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Par Pharm., Inc. v. Eagle Pharms., Inc.0
Recent Developments at the Intersection of Pharma, Patents, and Antitrust Law0
AstraZeneca AB v. Mylan Pharms. Inc.0
Purdue Pharma L.P. v. Collegium Pharm., Inc0
Celanese Int’l Corp. v. Int’l Trade Comm’n0
Geopolitical Data Barriers in Biomedicine: Resolving Sino–U.S. Regulatory Conflicts and Compliance Challenges Under Executive Order 141170
Selected Developments in Biotechnology Law and the Biotechnology Industry0
A 2023 Review of Legislation Aimed at Increasing Generic and Biosimilar Competition0
A Crisis on Patenting of “Ready-to-Use” Oral Liquid Formulations: Azurity Pharms., Inc. v. Alkem Lab’ys Ltd0
Seeds of Innovation: Exploring Intellectual Property Rights in the Realm of Genetically Modified Crops in India0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Challenges in Patenting Human Stem Cell Inventions: A Comparative Perspective in USA, Europe, and India—Is India Lagging?0
The Enablement and Written Description Requirements Through the Lens of the Federal Circuit's Actions (As Opposed to Its Words)0
Amarin Pharma, Inc. v. Hikma Pharms. USA, Inc.0
A Review of Judicial Opinions Interpreting the Novelty Provisions of the America Invents Act0
How a Dosage Regimen Patent for RRMS Treatment May Satisfy the Written Description Requirement—A Lesson from Novartis Pharmaceuticals Corp. v. Accord Healthcare, Inc.0
Cornell Rsch. Found., Inc. v. Vidal0
Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part II0
HIPAA, HIPPA, or HIPPO: What Really Is the Heath Insurance Portability and Accountability Act?0
Reflections on Pending Technical and Legal Issues in the R&D of COVID-19 Medical Products0
Research on the Intellectual Property Protection of Genetically Modified Crops in China0
Azurity Pharms., Inc. v. Alkem Lab’ys Ltd.0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Balancing Innovation and Biomedical Ethics within National Institutes of Health: Integrative and Regulatory Reforms for Artificial Intelligence-Driven Biotechnology0
0.025253057479858